a public good project by the
Synthesis
Company
of California

© 2026

David W. Fry | doi.page

0 works0 citations0 h-index

David W. Fry

Centre for Cancer Biology(AU)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Quinazolinone synthesis and applications, Synthesis and biological activity, Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms

Most-Cited Works

→ Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts(2004)1,233 cited
→ A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase(1994)802 cited
→ Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6(2005)501 cited
→ Rapid separation of low molecular weight solutes from liposomes without dilution(1978)421 cited
→ Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor(1998)417 cited
→ Induced Focal Adhesion Kinase (FAK) Expression in FAK-Null Cells Enhances Cell Spreading and Migration Requiring Both Auto- and Activation Loop Phosphorylation Sites and Inhibits Adhesion-Dependent Tyrosine Phosphorylation of Pyk2(1999)395 cited

→ Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor(1996)

321 cited

→ Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.(1995)260 cited

→ Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2008)221 cited

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.(1997)